Biotech Speaker Series

Join fellow alumni as panelists Michael Nerenberg, AB '77, and Yi Liu, P'19, share insight on the sector as part of our on-going Biotech Speaker Series.

Cost: $35/person in advance, $40/person for walk-ins; includes food and beverages

CLICK HERE TO REGISTER


Join fellow alumni, family and friends for the third Biotech Speaker Series event. Hear Michael Nerenberg, AB'77, and Yi Liu, P'19, discuss what's new in biotechnology and health care. Our panelists are experts in the field, with a focus on technology development, finance, and angel investing. Register today!

PANELISTS

Michael Nerenberg, AB'77, MD, Chief Medical Officer, Molecular Stethoscope



Dr. Nerenberg is a physician with training in internal medicine, molecular biology, clinical trials and diagnostics. He is the author of over 50 articles and 12 patents. He is currently Senior VP and CMO of Molecular Stethoscope, a startup Diagnostics company. Most recently, Dr. Nerenberg served as CTO and Senior VP for Medical Affairs and Business Development at Genoptix Inc. where he created the Compass Diagnostic product and served as the company’s initial medical director. Prior to joining Genoptix, Dr. Nerenberg served as President and Chief Technology Officer of Molecular Reflections, Inc., a biotechnology design and discovery company. He also served as the Senior Director of Molecular Biology for Nanogen, Inc., prior to which he was a faculty member in the department of Molecular and Experimental Medicine at the Scripps Institute. He received his B.A. in Chemistry from the University of Chicago and his M.D. from the Yale University School of Medicine, completed his residency in internal medicine at the Hospital of the University of Pennsylvania, and completed a fellowship at the National Cancer Institute.


Yi Liu, P'19, Chief Scientific Officer, Kura Oncology


Kura Oncology is a biotech company that develops a diverse pipeline of targeted therapeutics for solid tumors and blood cancers utilizing precision medicine approaches to identify patients most likely to benefit from treatments. Dr. Yi Liu has served as Chief Scientific Officer at Kura Oncology since October 2014. Prior to Kura, Dr. Liu served as Chief Scientific Officer of Wellspring Biosciences from May 2012 to September 2014. From April 2007 to January 2012, Dr. Liu served as Vice President of Drug Discovery at Intellikine, Inc., a private biopharmaceutical company. Previously, Dr. Liu served as head of the drug design group at the Genomics Institute of the Novartis Research Foundation (GNF) from August 2002 to January 2007. Earlier in his career, Dr. Liu worked as Senior Scientist at SGX Pharmaceuticals and Curagen from July 2001 to July 2002 and June 1999 to June 2001, respectively. Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his MS in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.

Event Contact
Kristina Peterson, MBA '90
kp2070@gmail.com
650.575.8399
Staff  Liaison
Ritu Prasad, AB'14
alumniclubs@uchicago.edu
+1.773.702.8955